+1-888-308-5802     
News Contact Us

Novartis announces Kymriah’s EU approval for blood cancer treatment

Author : Pankaj Singh | Published Date : 2018-08-27 

Novartis International AG has reportedly announced that it has received approval for its cancer therapy called Kymriah, issued by the European Commission. The approved gene-modifying treatment will be used initially to treat young adults up to 25 years of age suffering with B-Cell acute lymphoblastic leukemia and adult patients down with diffuse large B-cell lymphoma.

The one-time therapy that’s said to treat blood cancer by fighting T-cells in the patient’s system, will supposedly modify their bodies to fight off bad cells and then re-infuse new cells. The treatment is also approved in both indications in the United States.

According to sources close to the development, with an investment of $90.39 million Novartis will establish more facilities to continue manufacturing Kymriah. The pharma claimed therapy will cost about $475,000 for patients with acute lymphoblastic leukemia and $373,000 for patients afflicted with diffuse large B-cell lymphoma.

Formerly, Novartis had gained appreciation for its groundbreaking work pertaining to therapy exclusively for dying patients who didn’t respond to other drugs. However, officials were aghast by the prices, which apparently makes Kymriah one of the most expensive treatments.

In the United States, Novartis will only accept charges if patients with lymphoblastic leukemia show signs of recovery by the end of the first month. Meanwhile, discussions in terms of European pricing are still in progress.

In a statement to sources, Novartis revealed that Kymriah’s availability will differ for each country, based on factors like the establishment of licensed facilities for the appropriate indications and completion of a fixed payment agreement.

Post its launch in the United States, the treatment earned $28 million in sales, which is estimated to surpass $1 billion as soon as the demand begins to grow. In the meantime, the pharma firm plans to commence therapies to European patients at least by 2020.

About Author

Pankaj Singh

Pankaj Singh

Endowed with a post graduate degree in management and finance, Pankaj Singh has been a part of the online content domain for quite a while. Having worked previously as a U.K. insurance underwriter for two years, he now writes articles for fractovia.org and other online portals. He can be contacted at- [email protected] | https://twitter.com/PankajSingh2605

Related News

Chipmaker TSMC mulls over Germany for first Europe chip plant

Published Date: 2021-07-27         Author: Pankaj Singh

Taiwan Semiconductor Manufacturing Co Ltd (TSMC) stated that it is too early to talk about its factory expansion in Germany and that the talks are in the initial phases as the European Union seeks to reduce chip imports amid the supply shortage. The European Commission had conducted discussions w... Read More

COVID-19 cases surge in Australia, police warn of protest repeat

Published Date: 2021-07-26         Author: Pankaj Singh

Despite a weeks-long stay-at-home order, Australias most populated state reportedly recorded an increase in new COVID-19 cases, and police swore to suppress any recurrence of the raucous anti-lockdown rally over the weekend. New South Wales, which had imposed a lockdown in Sydney to curb the wide... Read More

LG commits to sustainability mission, aims to go 100% renewable by 2050

Published Date: 2021-07-23         Author: Pankaj Singh

South Korean multinational electronics firm LG Electronics Inc. recently announced its plans to transition to 100% renewable energy by 2050 as part of its sustainability strategy. For the record, the firm had earlier committed to carbon neutrality via the Zero Carbon 2030 initiative, which aims t... Read More

© 2021 Fractovia. All Rights Reserved